Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan Oronsky

Showing results (51-60 of 115) with videos related to

Pageof 12
Sort By:
Oncotarget|December 15, 2015
Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activityHongjuan Zhao, Shoucheng Ning, Jan Scicinski, et al.
Malaria Journal|May 29, 2015
From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malariaOzlem Yalcin, Bryan Oronsky, Leonardo J M Carvalho, et al.
Respiratory Medicine Case Reports|June 23, 2016
Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLCCorey A Carter, Bryan Oronsky, Scott Caroen, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 12, 2021
RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopeniaBryan Oronsky, Pedro Cabrales, Scott Caroen, et al.
Future Oncology (London, England)|July 28, 2023
TGF-β: the apex predator of immune checkpointsBryan Oronsky, Pedro Cabrales, Babak Alizadeh, et al.
Clinical Reviews in Allergy & Immunology|February 20, 2021
A Review of Persistent Post-COVID Syndrome (PPCS)Bryan Oronsky, Christopher Larson, Terese C Hammond, et al.
Medical Oncology (Northwood, London, England)|May 28, 2016
A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?Pedro Cabrales, Jan Scicinski, Tony Reid, et al.
Oncotarget|August 18, 2015
Going viral: a review of replication-selective oncolytic adenovirusesChristopher Larson, Bryan Oronsky, Jan Scicinski, et al.
Discovery Medicine|April 27, 2016
Rockets, radiosensitizers, and RRx-001: an origin story part IBryan Oronsky, Jan Scicinski, Shoucheng Ning, et al.
Clinical Epigenetics|February 3, 2017
The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicryHongjuan Zhao, Shoucheng Ning, Rosalie Nolley, et al.
Pageof 12

Showing results (51-60 of 115) with videos related to

Sort By:
Pageof 12
Oncotarget|December 15, 2015
Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activityHongjuan Zhao, Shoucheng Ning, Jan Scicinski, et al.
Malaria Journal|May 29, 2015
From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malariaOzlem Yalcin, Bryan Oronsky, Leonardo J M Carvalho, et al.
Respiratory Medicine Case Reports|June 23, 2016
Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLCCorey A Carter, Bryan Oronsky, Scott Caroen, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 12, 2021
RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopeniaBryan Oronsky, Pedro Cabrales, Scott Caroen, et al.
Future Oncology (London, England)|July 28, 2023
TGF-β: the apex predator of immune checkpointsBryan Oronsky, Pedro Cabrales, Babak Alizadeh, et al.
Clinical Reviews in Allergy & Immunology|February 20, 2021
A Review of Persistent Post-COVID Syndrome (PPCS)Bryan Oronsky, Christopher Larson, Terese C Hammond, et al.
Medical Oncology (Northwood, London, England)|May 28, 2016
A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?Pedro Cabrales, Jan Scicinski, Tony Reid, et al.
Oncotarget|August 18, 2015
Going viral: a review of replication-selective oncolytic adenovirusesChristopher Larson, Bryan Oronsky, Jan Scicinski, et al.
Discovery Medicine|April 27, 2016
Rockets, radiosensitizers, and RRx-001: an origin story part IBryan Oronsky, Jan Scicinski, Shoucheng Ning, et al.
Clinical Epigenetics|February 3, 2017
The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicryHongjuan Zhao, Shoucheng Ning, Rosalie Nolley, et al.
Pageof 12